Granhall C, Donsmark M, Blicher TM et al (2019) Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes
Understanding the difference between research-grade and pharmaceutical-grade peptides informs purchasing decisions that directly affect both safety and efficacy
To reflect these advances, Table 1 presents an updated and comprehensive summary of the pharmacological actions of SIN in various cardiovascular disease models, incorporating findings from in vitro and in vivo studies (Figure 5)
doi:10.1016/j.yfrne.2016.07.002 137
Vision changes during GLP-1 therapy typically stem from secondary factors rather than direct drug action on the eye
No effect of menstrual cycle on myofibrillar and connective tissue protein synthesis in contracting skeletal muscle